文献速递前列腺癌

多参数磁共振引导靶向穿刺与系统穿刺在前列腺癌诊断中的比较:系统综述与荟萃分析

Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis.
PubMed 文献 · J Urol · 2019-10-14

该研究纳入29项研究共13845例未穿刺过的男性,比较多参数磁共振引导靶向穿刺与系统穿刺对前列腺癌的诊断率。结果显示靶向穿刺对任何前列腺癌、临床显著癌及高级别癌的诊断率更高,而临床不显著癌诊断率无差异;排除系统穿刺可降低不显著癌诊断率而不影响显著癌或高级别癌的诊断率。

要点

  • 靶向穿刺对任何前列腺癌诊断率比系统穿刺高15%(95%CI 10-20,p<0.00001)。
  • 靶向穿刺对临床显著癌和高级别癌诊断率更高,风险差分别为11%和2%。
  • 排除系统穿刺可降低临床不显著癌诊断率(p=0.01),不影响显著癌诊断。

核心结论

  • 与系统穿刺相比,多参数磁共振引导靶向穿刺策略对任何、临床显著及高级别前列腺癌的诊断率显著更高。
  • 从靶向穿刺方案中排除系统穿刺与临床不显著前列腺癌诊断率降低相关,而不影响临床显著或高级别癌的诊断。

研究设计与样本

  • 系统综述与荟萃分析,检索Medline、Embase、Web of Science和Cochrane数据库至2019年。
  • 共纳入29项研究,13845例未穿刺过的男性。
  • 采用随机效应模型合并数据,遵循PRISMA声明,方案注册于PROSPERO(CRD42019128468)。

主要发现

  • 靶向穿刺对任何前列腺癌诊断率比系统穿刺高15%(95%CI 10-20,p<0.00001)。
  • 临床显著前列腺癌诊断风险差为11%(95%CI 0-20,p=0.05)。
  • 高级别前列腺癌诊断风险差为2%(95%CI 1-4,p=0.005)。
  • 临床不显著前列腺癌诊断风险差为0(95%CI -3至3,p=0.96)。
  • 排除系统穿刺显著改变磁共振策略与较低临床不显著癌诊断率之间的关联(p=0.01),但不影响临床显著或高级别癌诊断率。

临床怎么用

  • 对于未穿刺过的男性,多参数磁共振引导靶向穿刺可提高任何、临床显著及高级别前列腺癌的检出率。
  • 在靶向穿刺方案中排除系统穿刺可能减少临床不显著前列腺癌的过度诊断,且不影响显著癌或高级别癌的检出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Multiparametric magnetic resonance imaging with informed targeted biopsies has changed the paradigm of prostate cancer diagnosis. Randomized studies have demonstrated a diagnostic benefit of clinical significance for targeted biopsy compared to standard systematic biopsies. We evaluated whether multiparametric magnetic resonance imaging informed targeted biopsy has superior diagnosis rates of any, clinically significant, high grade and clinically insignificant prostate cancer compared to systematic biopsy in biopsy naïve men. MATERIALS AND METHODS: Data were searched in Medline®, Embase®, Web of Science and Evidence-Based Medicine Reviews-Cochrane Database of Systematic Reviews from database inception until 2019. Studies were selected by 2 authors independently, with disagreements resolved by consensus with a third author. Overall 1,951 unique references were identified and 100 manuscripts underwent full-text review. Data were pooled using random effects models. The meta-analysis is reported according to the PRISMA statement and the study protocol is registered with PROSPERO (CRD42019128468). RESULTS: Overall 29 studies (13,845 patients) were analyzed. Compared to systematic biopsy, use of multiparametric magnetic resonance imaging informed targeted biopsy was associated with a 15% higher rate of any prostate cancer diagnosis (95% CI 10-20, p <0.00001). This relationship was not affected by the study methodology (p=0.11). Diagnoses of clinically significant and high grade prostate cancer were more common in the multiparametric magnetic resonance imaging informed targeted biopsy group (risk difference 11%, 95% CI 0-20, p=0.05 and 2%, 95% CI 1-4, p=0.005, respectively) while there was no difference in diagnosis of clinically insignificant prostate cancer (risk difference 0, 95% CI -3 to 3, p=0.96). Notably, the exclusion of systematic biopsy in the multiparametric magnetic resonance imaging informed targeted biopsy arm significantly modified the association between a multiparametric magnetic resonance imaging strategy and lower rates of clinically insignificant prostate cancer diagnosis (p=0.01) without affecting the diagnosis rates of clinically significant or high grade prostate cancer. CONCLUSIONS: Compared to systematic biopsy a multiparametric magnetic resonance imaging informed targeted biopsy strategy results in a significantly higher diagnosis rate of any, clinically significant and high grade prostate cancer. Excluding systematic biopsy from multiparametric magnetic resonance imaging informed targeted biopsy was associated with decreased rates of clinically insignificant prostate cancer diagnosis without affecting diagnosis of clinically significant or high grade prostate cancer.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Goldberg H, Ahmad AE, Chandrasekar T, et al. Comparison of Magnetic Resonance Imaging and Transrectal Ultrasound Informed Prostate Biopsy for Prostate Cancer Diagnosis in Biopsy Naïve Men: A Systematic Review and Meta-Analysis. J Urol. 2019. PMID: 31609177. doi:10.1097/JU.0000000000000595

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。